Effects of Rosiglitazone alone and in combination with Atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

American Journal of Cardiology

Volumn 97, Issue 5, 2006, Pages 646-650

  Chu, Chih Sheng ^a   Lee, Kun Tai ^a   Lee, Ming Yi ^a   Su, Ho Ming ^a   Voon, Wen Chol ^a   Sheu, Sheng Hsiung ^a   Lai, Wen Ter ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; GELATINASE B; LOW DENSITY LIPOPROTEIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADIPONECTIN; AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CD40 LIGAND; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PYRROLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES; VASODILATOR AGENTS;

EID: 32844469572     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.09.101     Document Type: Article

References (26)

1. J. Kastelein What future for combination therapies? Int J Clin Pract 134 suppl 2003 45 50
2. M.I. Freed, R. Ratner, S.M. Marcovina, M.M. Kreider, N. Biswas, B.R. Cohen, J.D. Brunzell Rosiglitazone Study 108 Investigators Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus Am J Cardiol 90 2002 947 952
3. A.J. Lewin, M.S. Kipnes, L.F. Meneghini, D.J. Plotkin, I.T. Perevozskaya, S. Shah, D.L. Maccubbin, Y.B. Mitchel, J.A. Tobert Simvastatin/ Thiazolidinedione Study Group Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus a multicenter, randomized, double-blind, placebo-controlled trial Clin Ther 26 2004 379 389
4. G. Llaverias, D. Lacasa, M. Vinals, M. Vazquez-Carrera, R.M. Sanchez, J.C. Laguna, M. Alegret Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin Biochem Pharmacol 68 2004 155 163
5. S.M. Haffner, A.S. Greenberg, W.M. Weston, H. Chen, K. Williams, M.I. Freed Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 2002 679 684
6. F. Illan Gomez, M.S. Alcaraz Tafalla, M. Pascual Diaz, A. Carrillo Alcaraz Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus Med Clin (Barc) 123 2004 535 537
7. K.C. Tan, W.S. Chow, S.C. Tam, V.H. Ai, C.H. Lam, K.S. Lam Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus J Clin Endocrinol Metab 87 2002 563 568
8. N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, W. Koenig Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler Thromb Vasc Biol 23 2003 283 288
9. D.N. Tziakas, G.K. Chalikias, J.T. Parissis, E.I. Hatzinikolaou, E.D. Papadopoulos, G.A. Tripsiannis, E.G. Papadopoulou, I.K. Tentes, S.M. Karas, D.I. Chatseras Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration Int J Cardiol 94 2004 269 277
10. Z. Xu, S. Zhao, H. Zhou, H. Ye, J. Li Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome Clin Chem 50 2004 750 753
11. S. Kinlay, G.G. Schwartz, A.G. Olsson, N. Rifai, W.J. Sasiela, M. Szarek, P. Ganz, P. Libby Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Circulation 110 2004 386 391
12. N. Marx, A. Imhof, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, W. Maerz, V. Hombach, W. Koenig Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease Circulation 107 2003 1954 1957
13. A.G. Semb, S. van Wissen, T. Ueland, T. Smilde, T. Waehre, M.D. Tripp, S.S. Froland, J.J. Kastelein, L. Gullestad, T.R. Pedersen Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia down-regulatory effect of statin therapy J Am Coll Cardiol 41 2003 275 279
14. A.H. Wagner, M. Gebauer, B. Guldenzoph, M. Hecker 3-Hydroxy-3- methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells Arterioscler Thromb Vasc Biol 22 2002 1784 1789
15. W.S. Yang, C.Y. Jeng, T.J. Wu, S. Tanaka, T. Funahashi, Y. Matsuzawa, J.P. Wang, C.L. Chen, T.Y. Tai, L.M. Chuang Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients Diabetes Care 25 2002 376 380
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 20 1997 1183 1197
17. A. Ialenti, G. Grassia, P. Di Meglio, P. Maffia, M. Di Rosa, A. Ianaro Mechanism of the anti-inflammatory effect of thiazolidinediones. Relationship with the glucocorticoid pathway Mol Pharmacol 67 2005 1260 1268
18. U. Laufs, J.K. Liao Targeting Rho in cardiovascular disease Circ Res 87 2000 526 528
19. T.A. Pearson, G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon III, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers Centers for Disease Control and Prevention, American Heart Association Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
20. G.K. Shetty, P.A. Economides, E.S. Horton, C.S. Mantzoros, A. Veves Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk of diabetes Diabetes Care 10 2004 2450 2457
21. N. Ouchi, S. Kihara, Y. Arita, K. Maeda, H. Kuriyama, Y. Okamoto, K. Hotta, M. Nishida, M. Takahashi, T. Nakamura Novel modulator for endothelial adhesion molecules adipocyte-derived plasma protein adiponectin Circulation 100 1999 2473 2476
22. T. Pischon, C.J. Girman, G.S. Hotamisligil, N. Rifai, F.B. Hu, E.B. Rimm Plasma adiponectin levels and risk of myocardial infarction in men JAMA 291 2004 1730 1737
23. O. Grip, S. Janciauskiene, S. Lindgren Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes Inflamm Res 51 2002 58 62
24. K.T. Iida, Y. Kawakami, H. Suzuki, H. Sone, H. Shimano, H. Toyoshima, Y. Okuda, N. Yamada PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages FEBS Lett 520 2002 177 181
25. C.M. Dollery, J.R. McEwan, A.M. Henney Matrix metalloproteinase and cardiovascular disease Circ Res 77 1995 863 868
26. P. Libby, U. Schoenbeck, F. Mach, A.P. Selwyn, P. Ganz Current concepts in cardiovascular pathology the role of LDL cholesterol in plaque rupture and stabilization Am J Med 104 suppl 1998 14S 18S